Last reviewed · How we verify
ALA 2.5%
At a glance
| Generic name | ALA 2.5% |
|---|---|
| Sponsor | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- CROHN'S DISEASE
- ARTHRALGIA
- NASOPHARYNGITIS
- Nausea
- ABDOMINAL PAIN
- HEADACHE
- PYREXIA
- FATIGUE
- OROPHARYNGEAL PAIN
- RASH
- INFLUENZA
- ALOPECIA
Key clinical trials
- Nutritional Supplement for Treating Chemotherapy Induced Neuropathy (PHASE4)
- The Effect of Alpha Linolenic Acid Intake on Patients With Elevated Glycemic Status (NA)
- The IMmunotherapy Pleural 5-ALA PDT (PHASE2)
- Effect of Cross-linked Hyaluronic Acid Filler Versus Botulinum Toxin Type A (Botox) in Management of Gummy Smile (NA)
- Blood Bioavailability of Two Different Doses of a β-alanine Supplement (BIo-β) (NA)
- Study to Analyze the Efficacy of Chronic Intake With a β-alanine Supplement in Recreational Cyclists (NA)
- ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) (PHASE3)
- Study to Analyze the Efficacy of Acute Intake With a β-alanine Supplement in Recreational Cyclists (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALA 2.5% CI brief — competitive landscape report
- ALA 2.5% updates RSS · CI watch RSS
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. portfolio CI